Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study

Trial Profile

Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Eltrombopag (Primary) ; Immune globulin
  • Indications Immune thrombocytopenic purpura
  • Focus Therapeutic Use
  • Acronyms BRIDGING ITP
  • Most Recent Events

    • 16 Mar 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2018 as per ClinicalTrials.gov record.
    • 16 Mar 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2018 as per ClinicalTrials.gov record.
    • 07 Apr 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top